LifeMine valuation, funding and investors

LifeMine works in top-down drug discovery services, based in Cambridge, United States. Founded in 2017, it has about 32 employees.

Biotechnology Series E

VALUATION · TODAY

$2.02B −8% after Series E

Range $1.42B – $2.88B · Grade B

TODAY

+12 MO

$1.00B

$2.00B

$3.00B

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

Seed $5.00M

Series A $55.0M

Series B $50.0M

Series C $175M

Series D $75.0M

Series E $263M

ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then

HEADCOUNT · TODAY32 employees

−3%6m growth

−16%1y growth

−75%2y growth

100

200

Data from Jan 2021

TODAY

Predicted in 1 yr $1.86B −8% vs today

Predicted next raise $288M if a round comes

Winding-down probability 97%

Last round: Series E · $263M · Aug 2026
Valuation at last round: $2.00B · implied
Headcount: 32 · shrinking
Grade: B
Founded: 2017

How VCMC values companies →

LifeMine valuation today

VCMC values LifeMine at $2.0B today, with a range of $1.4B to $2.9B and a grade of B. The valuation starts from its last funding round, a Series E round in Aug 2026.

Valuation by date (137 rows)

Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.

LifeMine: valuation by date, as the model would have shown it on each date
Date	Valuation	Range	Predicted in 1 yr	Phase	Headcount	Trend	Grade	Winding-down probability
1 Jan 2016	$5.51M	$2.00M – $15.1M	$6.60M (+20%)	before first round	–	unknown	D	0%
13 Jan 2016	$20.0M	$13.1M – $60.9M	$40.0M (+100%)	after a round	–	unknown	C	0%
1 Feb 2016	$20.8M	$13.1M – $60.9M	$40.0M (+93%)	after a round	–	unknown	C	0%
1 Mar 2016	$21.9M	$13.1M – $60.9M	$40.0M (+82%)	after a round	–	unknown	C	0%
1 Apr 2016	$23.3M	$13.1M – $60.9M	$40.0M (+72%)	after a round	–	unknown	C	0%
1 May 2016	$24.6M	$13.1M – $60.9M	$40.0M (+62%)	after a round	–	unknown	C	0%
1 Jun 2016	$26.1M	$13.1M – $60.9M	$40.0M (+53%)	after a round	–	unknown	C	0%
1 Jul 2016	$27.7M	$13.1M – $60.9M	$40.0M (+45%)	after a round	–	unknown	C	0%
1 Aug 2016	$29.3M	$13.1M – $60.9M	$40.0M (+36%)	after a round	–	unknown	C	0%
1 Sep 2016	$31.1M	$13.1M – $60.9M	$40.0M (+29%)	after a round	–	unknown	C	0%
1 Oct 2016	$32.9M	$13.1M – $60.9M	$40.0M (+21%)	after a round	–	unknown	C	0%
1 Nov 2016	$34.9M	$13.1M – $60.9M	$40.0M (+14%)	after a round	–	unknown	C	0%
1 Dec 2016	$37.0M	$13.1M – $60.9M	$40.0M (+8%)	after a round	–	unknown	C	0%
1 Jan 2017	$39.2M	$13.1M – $60.9M	$40.0M (+2%)	after a round	–	unknown	C	0%
1 Feb 2017	$40.0M	$12.7M – $60.9M	$40.0M (0%)	after a round	–	unknown	C	0%
1 Mar 2017	$40.0M	$12.1M – $60.9M	$40.0M (0%)	after a round	–	unknown	C	0%
1 Apr 2017	$40.0M	$11.5M – $60.9M	$40.0M (0%)	after a round	–	unknown	C	0%
1 May 2017	$40.0M	$11.0M – $60.9M	$40.0M (0%)	after a round	–	unknown	C	0%
1 Jun 2017	$40.0M	$10.4M – $60.9M	$40.0M (0%)	after a round	–	unknown	C	0%
1 Jul 2017	$40.0M	$9.93M – $60.9M	$40.0M (0%)	after a round	–	unknown	C	0%
1 Aug 2017	$40.0M	$9.43M – $60.9M	$40.0M (0%)	after a round	–	unknown	C	0%
1 Sep 2017	$40.0M	$8.97M – $60.9M	$40.0M (0%)	after a round	–	unknown	C	0%
19 Sep 2017	$196M	$138M – $500M	$352M (+80%)	after a round	–	unknown	C	0%
1 Oct 2017	$200M	$138M – $500M	$352M (+76%)	after a round	–	unknown	C	0%
1 Nov 2017	$210M	$138M – $500M	$352M (+68%)	after a round	–	unknown	C	0%
1 Dec 2017	$220M	$138M – $500M	$352M (+60%)	after a round	–	unknown	C	0%
1 Jan 2018	$232M	$138M – $500M	$352M (+52%)	after a round	–	unknown	C	0%
1 Feb 2018	$243M	$138M – $500M	$352M (+45%)	after a round	–	unknown	C	0%
1 Mar 2018	$255M	$138M – $500M	$352M (+38%)	after a round	–	unknown	C	0%
1 Apr 2018	$268M	$138M – $500M	$352M (+32%)	after a round	–	unknown	C	0%
1 May 2018	$281M	$138M – $500M	$352M (+25%)	after a round	–	unknown	C	0%
1 Jun 2018	$295M	$138M – $500M	$352M (+19%)	after a round	–	unknown	C	0%
1 Jul 2018	$310M	$138M – $500M	$352M (+14%)	after a round	–	unknown	C	0%
1 Aug 2018	$326M	$138M – $500M	$352M (+8%)	after a round	–	unknown	C	0%
1 Sep 2018	$342M	$138M – $500M	$352M (+3%)	after a round	–	unknown	C	0%
1 Oct 2018	$352M	$135M – $500M	$352M (0%)	after a round	–	unknown	C	0%
1 Nov 2018	$352M	$128M – $500M	$352M (0%)	after a round	–	unknown	C	0%
1 Dec 2018	$352M	$122M – $500M	$352M (0%)	after a round	–	unknown	C	0%
1 Jan 2019	$352M	$116M – $500M	$352M (0%)	after a round	–	unknown	C	0%
1 Feb 2019	$352M	$110M – $500M	$352M (0%)	after a round	–	unknown	C	0%
1 Mar 2019	$352M	$105M – $500M	$352M (0%)	after a round	–	unknown	C	0%
1 Apr 2019	$352M	$100M – $500M	$352M (0%)	after a round	–	unknown	C	0%
1 May 2019	$352M	$95.3M – $500M	$352M (0%)	after a round	–	unknown	C	0%
1 Jun 2019	$352M	$90.6M – $500M	$352M (0%)	after a round	–	unknown	C	0%
1 Jul 2019	$352M	$86.2M – $500M	$352M (0%)	after a round	–	unknown	C	0%
1 Aug 2019	$352M	$81.9M – $500M	$352M (0%)	after a round	–	unknown	C	0%
1 Sep 2019	$352M	$77.9M – $500M	$352M (0%)	after a round	–	unknown	C	0%
1 Oct 2019	$352M	$74.1M – $500M	$352M (0%)	after a round	–	unknown	C	0%
1 Nov 2019	$352M	$70.4M – $500M	$352M (0%)	after a round	–	unknown	C	0%
1 Dec 2019	$352M	$67.0M – $500M	$352M (0%)	after a round	–	unknown	D	0%
1 Jan 2020	$352M	$63.7M – $500M	$352M (0%)	after a round	–	unknown	D	0%
1 Feb 2020	$352M	$60.6M – $500M	$352M (0%)	after a round	–	unknown	D	0%
1 Mar 2020	$352M	$57.7M – $500M	$352M (0%)	after a round	–	unknown	D	0%
1 Apr 2020	$352M	$54.9M – $500M	$352M (0%)	after a round	–	unknown	D	0%
1 May 2020	$352M	$52.2M – $500M	$352M (0%)	after a round	–	unknown	D	0%
1 Jun 2020	$352M	$49.6M – $500M	$352M (0%)	after a round	–	unknown	D	0%
1 Jul 2020	$352M	$47.3M – $500M	$352M (0%)	after a round	–	unknown	D	0%
1 Aug 2020	$352M	$44.9M – $500M	$352M (0%)	after a round	–	unknown	D	0%
1 Sep 2020	$352M	$42.7M – $500M	$352M (0%)	after a round	–	unknown	D	0%
1 Oct 2020	$352M	$40.6M – $500M	$352M (0%)	after a round	–	unknown	D	0%
1 Nov 2020	$352M	$38.6M – $500M	$352M (0%)	after a round	–	unknown	D	0%
1 Dec 2020	$352M	$36.7M – $500M	$352M (0%)	after a round	–	unknown	D	0%
1 Jan 2021	$352M	$34.9M – $500M	$352M (0%)	after a round	70	unknown	D	0%
9 Jan 2021	$358M	$235M – $815M	$536M (+50%)	after a round	70	unknown	C	0%
1 Feb 2021	$367M	$235M – $815M	$536M (+46%)	after a round	70	unknown	C	0%
1 Mar 2021	$378M	$235M – $815M	$536M (+42%)	after a round	70	unknown	C	0%
1 Apr 2021	$392M	$235M – $815M	$536M (+37%)	after a round	70	flat	C	0%
1 May 2021	$405M	$235M – $815M	$536M (+32%)	after a round	70	flat	C	0%
1 Jun 2021	$419M	$235M – $815M	$536M (+28%)	after a round	70	flat	C	0%
1 Jul 2021	$433M	$235M – $815M	$536M (+24%)	after a round	70	flat	C	0%
1 Aug 2021	$448M	$235M – $815M	$536M (+19%)	after a round	70	flat	C	0%
1 Sep 2021	$464M	$235M – $815M	$536M (+15%)	after a round	70	flat	C	0%
1 Oct 2021	$480M	$235M – $815M	$536M (+12%)	after a round	70	flat	C	0%
1 Nov 2021	$497M	$235M – $815M	$536M (+8%)	after a round	70	flat	C	0%
1 Dec 2021	$513M	$235M – $815M	$536M (+4%)	after a round	70	flat	C	0%
1 Jan 2022	$531M	$235M – $815M	$536M (+1%)	after a round	70	flat	C	0%
1 Feb 2022	$592M	$262M – $901M	$592M (0%)	after a round	110	growing	C	0%
1 Mar 2022	$592M	$264M – $901M	$592M (0%)	after a round	110	growing	C	0%
24 Mar 2022	$1.2B	$834M – $2.2B	$1.5B (+30%)	after a round	110	growing	B	0%
1 Apr 2022	$1.2B	$834M – $2.2B	$1.5B (+29%)	after a round	110	growing	B	0%
1 May 2022	$1.2B	$834M – $2.2B	$1.5B (+26%)	after a round	110	growing	B	0%
1 Jun 2022	$1.2B	$834M – $2.2B	$1.5B (+24%)	after a round	110	growing	B	0%
1 Jul 2022	$1.3B	$834M – $2.2B	$1.5B (+21%)	after a round	110	growing	B	0%
1 Aug 2022	$1.3B	$834M – $2.2B	$1.5B (+18%)	after a round	110	growing	B	0%
1 Sep 2022	$1.3B	$834M – $2.2B	$1.5B (+16%)	after a round	110	growing	B	0%
1 Oct 2022	$1.4B	$834M – $2.2B	$1.5B (+13%)	after a round	110	growing	B	0%
1 Nov 2022	$1.4B	$834M – $2.2B	$1.5B (+11%)	after a round	110	unknown	B	0%
1 Dec 2022	$1.5B	$892M – $2.3B	$1.6B (+11%)	after a round	150	growing	B	0%
1 Jan 2023	$1.5B	$892M – $2.3B	$1.6B (+8%)	after a round	150	growing	B	0%
1 Feb 2023	$1.6B	$892M – $2.3B	$1.6B (+5%)	after a round	150	growing	B	0%
1 Mar 2023	$1.6B	$892M – $2.3B	$1.6B (+2%)	after a round	150	growing	B	0%
1 Apr 2023	$1.6B	$894M – $2.3B	$1.6B (0%)	after a round	150	growing	B	0%
1 May 2023	$1.6B	$899M – $2.3B	$1.6B (0%)	after a round	150	growing	B	0%
1 Jun 2023	$1.6B	$904M – $2.3B	$1.6B (0%)	after a round	150	growing	B	0%
1 Jul 2023	$1.6B	$909M – $2.3B	$1.6B (0%)	after a round	150	growing	B	0%
1 Aug 2023	$1.6B	$914M – $2.3B	$1.6B (0%)	after a round	150	growing	B	0%
1 Sep 2023	$1.6B	$701M – $2.3B	$1.6B (0%)	after a round	150	unknown	C	0%
1 Oct 2023	$1.2B	$631M – $2.0B	$954M (-20%)	after a round	130	down	B	72%
1 Nov 2023	$1.2B	$600M – $2.0B	$937M (-20%)	after a round	130	down	B	72%
1 Dec 2023	$1.2B	$571M – $2.0B	$921M (-21%)	after a round	130	down	C	72%
1 Jan 2024	$1.1B	$543M – $2.0B	$904M (-21%)	after a round	130	down	C	72%
1 Feb 2024	$1.1B	$516M – $2.0B	$888M (-21%)	after a round	130	down	C	72%
1 Mar 2024	$956M	$483M – $1.9B	$692M (-28%)	after a round	120	down	C	97%
1 Apr 2024	$903M	$459M – $2.0B	$607M (-33%)	after a round	120	down	C	97%
1 May 2024	$881M	$437M – $2.0B	$588M (-33%)	after a round	120	down	C	97%
1 Jun 2024	$860M	$415M – $2.0B	$569M (-34%)	after a round	120	down	C	97%
1 Jul 2024	$883M	$395M – $2.0B	$598M (-32%)	after a round	120	flat	C	89%
1 Aug 2024	$921M	$382M – $2.1B	$637M (-31%)	after a round	130	flat	C	82%
1 Sep 2024	$944M	$363M – $2.1B	$665M (-30%)	after a round	130	flat	C	76%
1 Oct 2024	$968M	$346M – $2.2B	$693M (-28%)	after a round	130	flat	C	70%
1 Nov 2024	$956M	$317M – $2.1B	$694M (-27%)	after a round	110	down	C	64%
1 Dec 2024	$978M	$302M – $2.1B	$719M (-26%)	after a round	110	down	C	59%
1 Jan 2025	$987M	$287M – $2.1B	$728M (-26%)	after a round	110	down	D	56%
1 Feb 2025	$973M	$272M – $2.2B	$712M (-27%)	after a round	110	down	D	56%
1 Mar 2025	$961M	$260M – $2.2B	$697M (-27%)	after a round	110	down	D	56%
1 Apr 2025	$890M	$247M – $2.2B	$653M (-27%)	after a round	110	down	D	56%
1 May 2025	$910M	$235M – $2.2B	$679M (-25%)	after a round	110	flat	D	51%
1 Jun 2025	$929M	$224M – $2.2B	$703M (-24%)	after a round	110	flat	D	47%
1 Jul 2025	$350M	$185M – $977M	$203M (-42%)	after a round	58	shrinking	C	97%
1 Aug 2025	$319M	$167M – $909M	$185M (-42%)	after a round	46	shrinking	C	97%
1 Sep 2025	$306M	$159M – $890M	$177M (-42%)	after a round	46	shrinking	C	97%
1 Oct 2025	$281M	$145M – $836M	$163M (-42%)	after a round	38	shrinking	C	97%
1 Nov 2025	$270M	$138M – $819M	$156M (-42%)	after a round	38	shrinking	C	97%
1 Dec 2025	$259M	$131M – $802M	$149M (-42%)	after a round	38	shrinking	C	97%
1 Jan 2026	$248M	$125M – $786M	$143M (-42%)	after a round	38	shrinking	C	97%
1 Feb 2026	$231M	$115M – $746M	$134M (-42%)	after a round	33	shrinking	C	97%
1 Mar 2026	$222M	$110M – $732M	$134M (-39%)	after a round	33	shrinking	C	97%
1 Apr 2026	$204M	$104M – $616M	$134M (-34%)	after a round	33	shrinking	C	97%
1 May 2026	$194M	$98.5M – $597M	$133M (-31%)	after a round	32	shrinking	C	97%
1 Jun 2026	$186M	$93.6M – $582M	$133M (-28%)	after a round	32	shrinking	C	97%
1 Jul 2026	$178M	$89.1M – $569M	$133M (-25%)	after a round	32	shrinking	C	97%
1 Aug 2026	$169M	$84.1M – $551M	$132M (-22%)	after a round	31	shrinking	C	97%
7 Aug 2026	$2.0B	$1.4B – $2.9B	$2.0B (+1%)	after a round	31	shrinking	B	97%
8 Aug 2026	$2.0B	$1.4B – $2.9B	$2.0B (+1%)	after a round	31	shrinking	B	97%
1 Sep 2026	$2.0B	$1.4B – $2.9B	$2.0B (-2%)	after a round	31	shrinking	B	97%
1 Oct 2026	$2.0B	$1.4B – $2.9B	$1.9B (-6%)	after a round	32	shrinking	B	97%
24 Oct 2026	$2.0B	$1.4B – $2.9B	$1.9B (-8%)	after a round	32	shrinking	B	97%

Key facts about LifeMine

Founded: 2017
Headquarters: Cambridge, United States
Employees: about 32 -16% in a year
Total raised: $623M
Funding rounds: 6
Last round: Series E Aug 2026

LifeMine was founded in 2017 by Gregory Verdine and Weiqing Zhou.

LifeMine funding history

LifeMine has 6 funding rounds on record, from Jan 2016 to Aug 2026, $623M in total. None disclosed a valuation.

Series E 7 Aug 2026
Led by Milky Way Investments; with Bezos Expeditions, Gates Frontier, RA Capital, GV, LoLa Capital Partners, GlaxoSmithKline (GSK), Invus, ARCH Venture Partners.
Sources: finsmes.com, lifeminetx.com, biospace.com and 1 more
$263M
Series D 6 Aug 2026
Led by Milky Way Investments; with Bezos Expeditions, Gates Frontier, RA Capital, LoLa Capital Partners, Confidential investor.
Sources: biospace.com, pharmaphorum.com
$75M
Series C 23 Mar 2022
Led by Fidelity Management & Research Company; with Invus, 3W Partners Capital, GlaxoSmithKline (GSK), GV, ARCH Venture Partners, Blue Pool Capital, MRL Ventures Fund.
Sources: synbiobeta.com, goodwinlaw.com
$175M
Series B 8 Jan 2021
Led by Milky Way Investments; with GV, WuXi Healthcare Ventures, Foresite Capital, ARCH Venture Partners, Blue Pool Capital, MRL Ventures Fund.
Sources: biospace.com, synbiobeta.com
$50M
Series A 18 Sep 2017
Led by WuXi Healthcare Ventures; with Foresite Capital, ARCH Venture Partners, Boyu Capital, Blue Pool Capital, MRL Ventures Fund, Alexandria Venture Investments.
Sources: prnewswire.com, drugdeliverybusiness.com
$55M
Seed 12 Jan 2016
Led by WuXi Healthcare Ventures.
Sources: prnewswire.com
$5.0M

LifeMine investors

18 investors have backed LifeMine; Milky Way Investments, WuXi Healthcare Ventures and Fidelity Management & Research Company led at least one round.

Milky Way Investments lead, 3 rounds
WuXi Healthcare Ventures lead, 3 rounds
Fidelity Management & Research Company lead
ARCH Venture Partners 4 rounds
Blue Pool Capital 3 rounds
GV 3 rounds
Bezos Expeditions 2 rounds
Gates Frontier 2 rounds
GlaxoSmithKline (GSK) 2 rounds
Invus 2 rounds
LoLa Capital Partners 2 rounds
3W Partners Capital
Alexandria Venture Investments
Confidential investor

What LifeMine does

LifeMine works in biotechnology, with 10 recorded offerings and customers in biotechnology, pharmaceuticals and healthcare.

LifeMine Therapeutics, Inc. is an American biopharmaceutical company engaged in drug discovery and development, with a focus on precision medicines. The company utilizes a proprietary approach called Top-Down Drug DiscoveryTM, which integrates evolutionary insights from fungi with human genetics, genomics, bioinformatics, machine learning, and synthetic biology. LifeMine develops precision-engineered drugs for immune-mediated diseases and organ transplant rejection, and operates internationally with offices in the United States and Switzerland.

Description from Veridion's company data.

Products and services

Top-Down Drug Discovery Services
Precision Medicine Development
Calcineurin Inhibitor Development
Immune-Mediated Disease Therapeutics Development
Organ Transplantation Therapeutics Development
Genomics and Bioinformatics Platform Development
Synthetic Biology Application Services
Clinical-Stage Drug Development
Precision Medicine Research Services
Global Pharmaceutical Development

Markets

Biotechnology
Pharmaceuticals
Healthcare

Technology

Synthetic Biology
Machine Learning
Bioinformatics
Genomics
Calcineurin Inhibitor Development

Business model

Business-to-Business
Manufacturing

Industry codes (NAICS)

541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match

Questions about LifeMine

What is LifeMine worth?

Valuation $2.0B (range $1.4B to $2.9B), as of 24 Oct 2026.

Has LifeMine raised money?

LifeMine has 6 funding rounds on record, from Jan 2016 to Aug 2026, $623M in total. None disclosed a valuation.

Who has invested in LifeMine?

Milky Way Investments, WuXi Healthcare Ventures, Fidelity Management & Research Company, ARCH Venture Partners, Blue Pool Capital and GV, and 12 more. Lead investors include Milky Way Investments, WuXi Healthcare Ventures and Fidelity Management & Research Company.

How many people work at LifeMine?

About 32, down 16% over the last year. Headcount rose from 70 in Jan 2021 to 150 in Dec 2022, then fell to 32 in Sep 2026.

What does LifeMine do?

LifeMine works in biotechnology, with 10 recorded offerings and customers in biotechnology, pharmaceuticals and healthcare. Its main offerings are top-down drug discovery services, precision medicine development and calcineurin inhibitor development.

When was LifeMine founded, and where is it based?

LifeMine was founded in 2017 and is based in Cambridge, United States. It has about 32 employees, down 16% over the last year.

How we value companies Report an issue

LifeMine valuation, funding and investors

LifeMine valuation today

Key facts about LifeMine

LifeMine funding history

Series E 7 Aug 2026

Series D 6 Aug 2026

Series C 23 Mar 2022

Series B 8 Jan 2021

Series A 18 Sep 2017

Seed 12 Jan 2016